Belumosudil

Phase 2

Sanofi (SNYNF)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

4 competitors in Chronic Graft Versus Host Disease

INCYINCA034176

Phase 3

SNYBelumosudil 200 mg QD

Phase 2

INCYAxatilimab

Phase 2

INCYBest available Treatment (BAT)

Phase 2

View Full Landscape

Drug Information

Target Indication

Chronic Graft Versus Host Disease

Clinical Trial

NCT07116031

Last updated: 2/13/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

SNYNF

Sanofi

Biotechnology•North America•NASDAQ

Related Pipeline

IrbesartanPhase 3

Atrial Fibrillation

Teriflunomide (HMR1726)Phase 3

Multiple Sclerosis

DTaP-IPV-HB-PRP~T vaccinePhase 3

Diphtheria

Insulin glargine/lixisenatide Fixed Ratio CombinationPhase 3

Type 2 Diabetes

teriflunomide HMR1726Phase 3

Multiple Sclerosis

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts